Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
jsp191 save search
Jasper Therapeutics Announces Positive Clinical Data from Investigator Sponsored Study of JSP191 Conditioning in Fanconi Anemia Patients at IEWP Annual Meeting
Published: 2022-09-26 (Crawled : 14:00) - biospace.com/
JSPR | $22.0 -2.31% -2.36% 78K
|
|
| O: 4.93%
H: 35.29%
C: -4.71%
jsp191 meeting anemia therapeutics positive study
Jasper Therapeutics Announces FDA Fast Track Designation for JSP191, a novel monoclonal antibody targeting CD117
Published: 2022-09-15 (Crawled : 13:00) - biospace.com/
JSPR | $22.0 -2.31% -2.36% 78K
|
|
| O: 13.53%
H: 7.95%
C: -13.91%
jsp191 fda designation antibody therapeutics fast track designation
Jasper Therapeutics Announces Treatment of First Patient in Study of JSP191 Conditioning in Patients with Fanconi Anemia
Published: 2022-05-17 (Crawled : 17:00) - biospace.com/
JSPR | $22.0 -2.31% -2.36% 78K
|
|
| O: 0.34%
H: 11.74%
C: -0.34%
jsp191 treatment anemia therapeutics
Jasper Therapeutics Announces Plans for Registrational Study of JSP191 in Older Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation after Type C FDA Meeting
Published: 2022-04-28 (Crawled : 19:00) - biospace.com/
JSPR | $22.0 -2.31% -2.36% 78K
|
|
| O: 16.64%
H: 0.0%
C: -17.18%
jsp191 fda leukemia therapeutics order acute myeloid leukemia
Jasper Therapeutics Announces Updated Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning Agent in Older Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation
Published: 2022-04-26 (Crawled : 21:00) - biospace.com/
JSPR | $22.0 -2.31% -2.36% 78K
|
|
| O: -0.36%
H: 2.2%
C: 1.1%
jsp191 leukemia trial therapeutics order phase 1 acute myeloid leukemia
Jasper Therapeutics to Present Updated Data on JSP191 Conditioning in SCID Patients at the 2022 Clinical Immunology Society Annual Meeting
Published: 2022-03-31 (Crawled : 16:00) - biospace.com/
JSPR | $22.0 -2.31% -2.36% 78K
|
|
| O: 2.69%
H: 7.27%
C: 3.2%
jsp191 immunology therapeutics
Jasper Therapeutics Announces JSP191 Phase 1b MDS/AML Late Breaking Data Presentation at the 2022 Transplantation & Cellular Therapy Tandem Meetings of ASTCT and CIBMTR
Published: 2022-02-24 (Crawled : 00:00) - biospace.com/
JSPR | $22.0 -2.31% -2.36% 78K
|
|
| O: 1.44%
H: 0.0%
C: 0.0%
jsp191 phase 1b therapeutics presentation cel phase 1 therapy aml phase 2b
Jasper Therapeutics to Present Data on JSP191 Conditioning in SCID patients at the 2021 American Society of Hematology Annual Meeting
Published: 2021-12-08 (Crawled : 13:30) - globenewswire.com
JSPR | $22.0 -2.31% -2.36% 78K
|
|
| O: 5.09%
H: 6.21%
C: 5.34%
ema therapeutics
Jasper Therapeutics Announces Research Collaboration with AVROBIO to Evaluate JSP191 as Conditioning Agent in Clinical Studies of Ex Vivo Lentiviral Gene Therapy
Published: 2021-11-09 (Crawled : 19:00) - biospace.com/
JSPR | $22.0 -2.31% -2.36% 78K
|
|
| O: -2.22%
H: 0.0%
C: 0.0%
AVRO | $1.205 0.42% 0.41% 54K
|
Health Technology
|
| O: -1.63%
H: 0.5%
C: -3.64%
gene therapy therapy collaboration research
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.